Arrowhead Official Reaffirms 2010 Calando Partnership Goal | GenomeWeb

Arrowhead Research's top executive this week reaffirmed that the firm's subsidiary Calando Pharmaceuticals is poised to complete enrollment in a phase I trial of its siRNA-based cancer drug CALAA-01 shortly and to strike its first industry partnership before the end of 2010.

"If data from the [ongoing] clinical trial continue to be positive, the value of such a deal could increase as the trial progresses," Arrowhead President and CEO Christopher Anzalone said in a letter to company shareholders.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Wired's Sarah Zhang writes that the fight over who developed the CRISPR/Cas9 genome editing tool first underscores the history of parallel discoveries in science.

Recent research indicates that the benefit of having a number of scientists all living and working in a certain area is eroding.

Tomas Lindahl, Paul Modrich, and Aziz Sancar share this year's Nobel Prize in Chemistry for their studies of DNA repair mechanisms.